SHARYNA ROSATI: Open Payments
NPI 1588053607 · PITTSBURGH, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,028 in 50 payments from 13 companies in 2025. Trend: 2023 $1,075 · 2024 $1,001 · 2025 $1,028
Food & beverage: $1,008Education: $20
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 15 | $290 |
| AstraZeneca Pharmaceuticals LP | 7 | $175 |
| E.R. Squibb & Sons, L.L.C. | 6 | $117 |
| Novartis Pharmaceuticals Corporation | 3 | $72 |
| SCPHARMACEUTICALS INC. | 4 | $69 |
| Boston Scientific Corporation | 3 | $60 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $51 |
| BridgeBio Pharma, Inc. | 2 | $46 |
| Novo Nordisk Inc | 2 | $44 |
| Edwards Lifesciences Corporation | 1 | $39 |
Products named: JARDIANCE, WAINUA, CAMZYOS, LEQVIO, FUROSCIX, FARXIGA, Kerendia, Attruby.
Industry payments across PA — which companies pay providers there.
